One-Shot gene therapy aims to free patients from monthly eye injections
NCT ID NCT05984927
Summary
This early-stage study is testing a one-time gene therapy injection for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if this single treatment can safely reduce the need for the frequent anti-VEGF injections patients currently require to control the disease. The study will involve about 20 participants to first check safety and see if the therapy shows any early signs of helping.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cincinnati Eye Institute
Cincinnati, Ohio, 45242, United States
-
Retina Consultants of Texas
Bellaire, Texas, 77401, United States
-
Sunnybrook Ophthalmology and Vision Services
Toronto, Ontario, M4N 3M5, Canada
-
Vancouver Coastal Health Research Institute
Vancouver, British Columbia, V5Z 3N9, Canada
-
Vitreous Retina Macula Specialists of Toronto
Toronto, Ontario, M8X 2X3, Canada
Conditions
Explore the condition pages connected to this study.